US45781K2042 - ADR
2.58 +0.28 (+12.17%)
After market: 2.44 -0.14 (-5.43%)
Innate Pharma stock drops as FDA imposes partial clinical hold on two trials for lymphoma candidate lacutamab, after a fatal rare blood disorder. Read more here.
The company's collaboration agreement with Sanofi could soon pay off.
Innate Pharma (IPHA) stock rose ~15% after the company said it signed a license agreement with Takeda. Read more here